Clinical trials for Langerhans cell histiocytosis
17 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGN/ANCT07371182Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone LesionsWest China Second University Hospital
- RECRUITINGN/ANCT07431060Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisWest China Second University Hospital
- ACTIVE NOT RECRUITINGPhase 2NCT07204041Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPhase 2NCT07022834Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in ChildrenWest China Second University Hospital · PI: Ju Gao, MD
- RECRUITINGPhase 2NCT07187193Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences · PI: Xinxin XX Cao, doctor
- ENROLLING BY INVITATIONPhase 1NCT06902792Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsSecond Affiliated Hospital of Wenzhou Medical University
- RECRUITINGPhase 2NCT06582745Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibCook Children's Health Care System · PI: Anish Ray, MD
- RECRUITINGPhase 2NCT05828069A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisNational Cancer Institute (NCI) · PI: Carl E Allen
- RECRUITINGNCT06197204Biomarkers for Diagnostic, Prognostic and of Response to Treatment in Adult Langerhans Cell HistiocytosisAssistance Publique - Hôpitaux de Paris
- RECRUITINGPhase 2NCT06078969Oral Prednisone in Treating LCH of Bone in Childhood and AdolescenceShanghai Changzheng Hospital
- RECRUITINGPhase 2NCT05997602To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCHShanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PI: Rui Zhang, MD
- RECRUITINGPhase 2NCT04943198Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory HistiocytosisAnna Raciborska · PI: Anna Raciborska
- RECRUITINGPhase 3NCT04943211Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT ImagingAnna Raciborska · PI: Anna Raciborska
- RECRUITINGPhase 3NCT04773366A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained ProtocolShanghai Children's Medical Center · PI: Yi-Jin Gao, MD
- RECRUITINGPHASE2, PHASE3NCT02205762LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisNorth American Consortium for Histiocytosis · PI: Milen Minkov, MD, Ph.D
- RECRUITINGPhase 3NCT02670707Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)Baylor College of Medicine · PI: Olive Eckstein, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02425904Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related DisordersDana-Farber Cancer Institute · PI: Barbara Degar, MD